Cantor Fitzgerald Starts Oncothyreon (ONTY) at Buy; All About Stimuvax

Cantor Fitzgerald initiates coverage on Oncothyreon (NASDAQ: ONTY) with a Buy. PT $11.00.

Cantor analyst said, "We initiate coverage with a Buy. This is based on our belief that Stimuvax, the company's Phase III therapeutic cancer vaccine, has a higher likelihood of successful clinical trial outcome than failure."

"Our conviction is based on a number of parameters, including the growing body of knowledge regarding how immunotherapeutic vaccines work and factors such as clinical trial design."

For an analyst ratings summary and ratings history on Oncothyreon click here. For more ratings news on Oncothyreon click here.

Shares of Oncothyreon closed at $6.32 yesterday, with a 52 week range of $2.99-$11.59.

---

Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
• UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
• Wunderlich Securities Starts Beacon Roofing Supply (BECN) at Buy

Create E-mail Alert Related Categories

New Coverage

Related Entities

Cantor Fitzgerald

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter